Antigenics is involved in the identification, development and commercialization of novel medicines for treating cancer and life-threatening infectious diseases.

Cell Therapeutics Inc. develops, acquires, and commercializes innovative treatments for cancer, and is developing a diversified portfolio of oncology products focused on identifying new, less toxic, and more effective cancer therapies.
 

Ception Therapeutics is an emerging biopharmaceutical company focused on the discovery and development of novel products to address unmet medical needs.

Chroma Therapeutics is the first biotechnology company founded to exploit the potential of chromatin biology for cancer drug discovery. Chroma is focused on the identification of novel anti-cancer agents that combine the efficacy of cytotoxics with the tumour cell selectivity of modern targeted therapeutics.

Confluent is a private medical device company pioneering the development of In-situ-polymerized Biomaterials. These materials have almost universal applications across minimally invasive surgery because they allow the safe, simple, and rapid formation of customized implants at the site of disease. This process can take place rapidly when two aqueous solutions of molecularly designed synthetic polymers mix together. Confluent's vision is to address unmet needs in surgery and interventional procedures using its technology platform of in situ polymerization.

Elusys Therapeutics, Inc. is focused on the development of the Heteropolymer System, a novel platform technology to treat a wide variety of blood-borne infections and autoimmune diseases.

Iomai specializes in developing the next generation of vaccines using TCI (transcutaneous immunization). The company is pioneering the delivery to the skin of potent biological molecules for vaccination and immuno-modulation that will prevent or treat a broad range of diseases.

Founded in 1989, La Jolla Pharmaceutical Company is a biotechnology company leading the development and marketing of novel therapeutics for antibody-mediated autoimmune diseases, such as lupus and antibody-mediated thrombosis.

LifeCell Corporation develops and markets biologic products for the repair or replacement of damaged or inadequate tissues. The Company's core preservation technology produces an acellular tissue matrix, which retains the essential biochemical and structural components necessary for normal tissue regeneration.

Light Sciences Oncology (LSO) has developed an innovative, practical, targeted therapy that can destroy previously untreatable tumors, utilizing best-in-class light activated drug and novel light generation devices to destroy tumors from the inside out for cancers such as hepatoma, metastatic colorectal cancer and glioma.

Orthovita is a unique spine/orthopaedic surgical biomaterials company offering advanced bone regeneration and soft tissue healing technologies. Their experience lies in developing and distributing novel, high-tech, synthetic-based biomaterial products. Orthovita currently has four key commercial product platforms: Vitoss Bone Graft Substitute, Vitagel Surgical Hemostat, Cortoss Synthetic Cortical Bone, and Imbibe Delivery and Disposable Systems.
 

Rinat is a privately held biopharmaceutical company dedicated to the discovery and commercialization of novel antibody based drugs and drug targets for the major mental and neurodegenerative diseases and disorders of the nervous system. Rinat Neuroscience was founded in 2001 and was acquired by Pfizer Inc in April 2006.
 

Symphogen A/S was established with the aim to commercialize a novel patented polyclonal antibody technology, designated the Symphage technology. This proprietary technology offers a method for the production of unlimited amounts of highly purified, antigen-specific, polyclonal antibody preparations, designated symphobodies.

Targeted Genetics Corp. is a leader in gene delivery technology and in the development of therapeutic products based on gene delivery.